Brendan M. Johnson

1.8k total citations
39 papers, 1.2k citations indexed

About

Brendan M. Johnson is a scholar working on Oncology, Surgery and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Brendan M. Johnson has authored 39 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 13 papers in Surgery and 10 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Brendan M. Johnson's work include Nausea and vomiting management (12 papers), Pharmacological Effects and Toxicity Studies (9 papers) and Drug Transport and Resistance Mechanisms (8 papers). Brendan M. Johnson is often cited by papers focused on Nausea and vomiting management (12 papers), Pharmacological Effects and Toxicity Studies (9 papers) and Drug Transport and Resistance Mechanisms (8 papers). Brendan M. Johnson collaborates with scholars based in United States, United Kingdom and Netherlands. Brendan M. Johnson's co-authors include William N. Charman, Christopher J. H. Porter, Kim L. R. Brouwer, Alexander R. Cobitz, Louis Holdstock, Amy M. Meadowcroft, John J. Lepore, Delyth Jones, Peijin Zhang and John D. Schuetz and has published in prestigious journals such as Journal of Clinical Oncology, Journal of the American Society of Nephrology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Brendan M. Johnson

39 papers receiving 1.2k citations

Peers

Brendan M. Johnson

ONCOL

HEMAT

PPCH

PHARM

Balaji Agoram United States

Tomoe Fujita Japan

Simon Joel United Kingdom

Armin Wolf Switzerland

Milin Acharya United States

Jianguo Zhi United States

Jan Jaap van Lier United States

Masamitsu Maekawa Japan

Kari M. Morrissey United States

Balaji Agoram United States

Brendan M. Johnson

306 ×0.8

ONCOL

140 ×0.4

HEMAT

331 ×1.6

102 ×0.5

PPCH

192 ×1.1

PHARM

Citations per year, relative to Brendan M. Johnson Brendan M. Johnson (= 1×) peers Balaji Agoram

Countries citing papers authored by Brendan M. Johnson

Since Specialization

Citations

This map shows the geographic impact of Brendan M. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brendan M. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brendan M. Johnson more than expected).

Fields of papers citing papers by Brendan M. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brendan M. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brendan M. Johnson. The network helps show where Brendan M. Johnson may publish in the future.

Co-authorship network of co-authors of Brendan M. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Brendan M. Johnson. A scholar is included among the top collaborators of Brendan M. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brendan M. Johnson. Brendan M. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caltabiano, S, et al.. (2019). Effect of renal function and dialysis modality on daprodustat and predominant metabolite exposure. Clinical Kidney Journal. 12(5). 693–701. 16 indexed citations

Holdstock, Louis, Amy M. Meadowcroft, Brendan M. Johnson, et al.. (2015). Four-Week Studies of Oral Hypoxia-Inducible Factor–Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia. Journal of the American Society of Nephrology. 27(4). 1234–1244. 156 indexed citations

Winer, Eric S., Howard Safran, Frédéric Forget, et al.. (2015). Safety and efficacy of eltrombopag (EPAG) vs placebo (PBO) for treatment of chemotherapy (CTx)-induced thrombocytopenia (TCP) in patients (Pts) with solid tumors receiving gemcitabine (GEM)-based CTx: A phase 2 study.. Journal of Clinical Oncology. 33(15_suppl). 9602–9602. 1 indexed citations

Kranke, Peter, John Paul Thompson, Leopold Eberhart, et al.. (2014). Comparison of vestipitant with ondansetron for the treatment of breakthrough postoperative nausea and vomiting after failed prophylaxis with ondansetron. British Journal of Anaesthesia. 114(3). 423–429. 13 indexed citations

Mudd, Paul N., et al.. (2013). Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopenia. Cancer Chemotherapy and Pharmacology. 71(6). 1507–1520. 16 indexed citations

Johnson, Brendan M., et al.. (2013). Effect of food and gemfibrozil on the pharmacokinetics of the novel prolyl hydroxylase inhibitor GSK1278863. Clinical Pharmacology in Drug Development. 3(2). 109–117. 39 indexed citations

Chung, Vincent, Elisabeth I. Heath, William R. Schelman, et al.. (2011). First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer Chemotherapy and Pharmacology. 69(3). 733–741. 66 indexed citations

Adams, Laurel M., Brendan M. Johnson, John W. Bauman, et al.. (2010). Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer. Cancer Chemotherapy and Pharmacology. 67(4). 783–790. 5 indexed citations

Zamuner, Stefano, et al.. (2010). Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine. British Journal of Clinical Pharmacology. 70(4). 537–546. 11 indexed citations

10.

Bauman, John W., Joyce Antal, Laurel M. Adams, et al.. (2010). Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist. Investigational New Drugs. 30(2). 662–671. 6 indexed citations

11.

Schmith, Virginia D., Brendan M. Johnson, Lakshmi Vasist, et al.. (2009). The Effects of a Short Course of Antibiotics on Alvimopan and Metabolite Pharmacokinetics. The Journal of Clinical Pharmacology. 50(3). 338–349. 2 indexed citations

12.

Mondick, John, Brendan M. Johnson, Mark Sale, et al.. (2009). Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months. European Journal of Clinical Pharmacology. 66(1). 77–86. 14 indexed citations

13.

Adams, Laurel M., Brendan M. Johnson, Ke Zhang, et al.. (2009). Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron. Supportive Care in Cancer. 17(9). 1187–1193. 7 indexed citations

14.

Johnson, Brendan M., et al.. (2009). Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Supportive Care in Cancer. 17(9). 1177–1185. 14 indexed citations

15.

Johnson, Brendan M., Ivy Song, Kimberly K. Adkison, et al.. (2006). Evaluation of the Drug Interaction Potential of Aplaviroc, a Novel Human Immunodeficiency Virus Entry Inhibitor, Using a Modified Cooperstown 5 + 1 Cocktail. The Journal of Clinical Pharmacology. 46(5). 577–587. 20 indexed citations

16.

Chandra, Priyamvada, Brendan M. Johnson, Peijin Zhang, Gary M. Pollack, & Kim L. R. Brouwer. (2005). MODULATION OF HEPATIC CANALICULAR OR BASOLATERAL TRANSPORT PROTEINS ALTERS HEPATOBILIARY DISPOSITION OF A MODEL ORGANIC ANION IN THE ISOLATED PERFUSED RAT LIVER. Drug Metabolism and Disposition. 33(8). 1238–1243. 28 indexed citations

17.

Johnson, Brendan M., Peijin Zhang, John D. Schuetz, & Kim L. R. Brouwer. (2005). CHARACTERIZATION OF TRANSPORT PROTEIN EXPRESSION IN MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN (MRP) 2-DEFICIENT RATS. Drug Metabolism and Disposition. 34(4). 556–562. 95 indexed citations

18.

Ghibellini, Giulia, Brendan M. Johnson, Richard J. Kowalsky, William D. Heizer, & Kim L. R. Brouwer. (2004). A novel method for the determination of biliary clearance in humans. The AAPS Journal. 6(4). 45–52. 33 indexed citations

19.

Johnson, Brendan M., Weiqing Chen, Ronald T. Borchardt, William N. Charman, & Christopher J. H. Porter. (2003). A Kinetic Evaluation of the Absorption, Efflux, and Metabolism of Verapamil in the Autoperfused Rat Jejunum. Journal of Pharmacology and Experimental Therapeutics. 305(1). 151–158. 61 indexed citations

20.

Silverstone, Peter H., et al.. (1992). Ondansetron, a 5-HT3 receptor antagonist, partially attenuates the effects of amphetamine. International Clinical Psychopharmacology. 7(1). 37–44. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact